Tamoxifen: Role in Breast Cancer Treatment

Authors

  • S. Ali School of Life Sciences, Jawaharlal Nehru University, New Delhi, India
  • N. Mondal School of Life Sciences, Jawaharlal Nehru University, New Delhi, India

Abstract

 

Breast cancer is one of the most common cancers among women worldwide. In the last two decades, there have been various therapies proposed for the treatment and prevention of breast cancer. One of them is targeted hormonal therapy (THT) for the estrogen and its receptor in breast cancer. The synthetic selective estrogen receptor modulator, tamoxifen is in the use for treating, estrogen receptor positive breast cancer from the last 30 years. US FDA approved tamoxifen as a drug in 1998. Tamoxifen reduces the incidence of breast cancer and thousand of lives been saved by preventing the risk of cancer in premenopausal women. Tamoxifen is beneficial as an adjuvant therapy. The major clinical problem arises due to the relapse in therapy and side effects associated with this drug. Various strategies, like the use of phytochemicals, biomarkers and inhibitors are in use to overcome these obstacles. They have a varying role in terms of estrogenic activity. The combinatorial approach of these results is a more effective treatment than a single drug system. The pharmacological designing of drug in response to the dose and effect: investigated in the clinical trials and observational studies is performed on the molecular basis. These findings suggest the use of low dose of tamoxifen at appropriate site along with the combinational strategy, as beneficial approach is in the treatment of breast cancer. This review focuses on selective estrogen receptor modulators, specially tamoxifen and aromatase inhibitors given alone or in the combination for effective therapies in estrogen receptor positive breast cancer patients.

Keywords: Tamoxifen, breast cancer, estrogen, estrogen receptor, selective estrogen receptor modulators, aromatase inhibitors

Cite this Article

Ali and Mondal. Tamoxifen: Role in Breast Cancer Treatment. Research and Reviews: Journal of Oncology and Hematology. 2016; 5(1): 1–19p.

 

Downloads

Additional Files

Published

2016-05-11

Issue

Vol. 5 No. 1 (2016)

Section

Review Articles

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is notpublished already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  • I/We also agree to the authorship of the article in the following order:

Author’s name

 

1. ________________

2. ________________

3. ________________

_______________

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.